New Horizons in the Management of Advanced Breast Cancer

Slides:



Advertisements
Similar presentations
© MediPaper 2016 ASCO 2016 Palbociclib (Ibrance™) Data MediPaper Study / AbstractPhIndicationLineNN BiomarkerMethodologyArms1 o EPORRCBRDCRmPF S (Mo) PFS.
Advertisements

Product Pipeline Neratinib across the breast cancer therapy spectrum
Cyclin Kinases inhibitors and beyond
PrECOG 0102: A Randomized, Double-Blind Phase II Trial of Fulvestrant plus Everolimus or Placebo in Post-Menopausal Women with Hormone-Receptor Positive,
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Endocrine Therapy for Metastatic Breast Cancer
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
SWAG SSG Breast Cancer Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
UKBCG UK Breast Cancer Group.
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Product Pipeline Neratinib across the breast cancer therapy spectrum
Evolving Paradigms in the Management of HR-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
Neoadjuvant Therapy for HER2-Positive Breast Cancer
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Her2-positive breast cancer: updating current best practice
BRCA, HRR Deficiency, and PARP Inhibitors
New Patient Journeys in Non-small cell lung cancer
Progression After Cancer Immunotherapy in Advanced NSCLC
سرطان الثدي Breast Cancer
Overall Program Goals. Overall Program Goals Current Approaches.
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.
PARP Inhibitors and Cancer: What Do You Need to Know?
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
CDK4/6 Inhibitors in Practice
Managing gBRCA-Positive Metastatic Breast Cancer
Treating mRCC After Initial Antiangiogenic Therapy:
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Treatment of HR+ Breast Cancer: A Clinical Update
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Hormone Receptor-Positive Advanced Breast Cancer:
Immunotherapy for cSCC
Vincenzo Adamo Luminal Metastatic Breast Cancer:
Serum vs FNA:.
Breast Cancer Statistics
Best Practices in Lymph Node Mapping and Localization: Melanoma
The Road to Quality Improvement in HER2-Positive Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Introduction Advanced Hormone Receptor-Positive Breast Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
New Paradigms in HR-Positive Advanced Breast Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Practical Guidance on the Management of Pan-Negative NSCLC
Product Pipeline Neratinib across the breast cancer therapy spectrum
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
CDK4/6 Inhibitors.
Real-World Evidence.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moving Care Forward in Advanced Gastric Cancer
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Combining Immunotherapy and Chemotherapy in NSCLC
Presentation transcript:

New Horizons in the Management of Advanced Breast Cancer

Program Overview

Recent Therapeutic Advances in HR-Positive, HER2-Negative Breast Cancer

High Rate of ESR1 Mutations Identified in cfDNA Analysis of Plasma Samples From BOLERO-2

Prophylactic Mouth Rinse for Everolimus-Related Stomatitis

Subgroup Analysis of Stomatitis in the BALLET Study

The PI3K Pathway in Breast Cancer

Phase 3 BELLE-2: Buparlisib + Fulvestrant in Advanced HR-Positive Disease

Adjuvant ET ± Everolimus: Phase 3 Trials

PALLAS: Adjuvant ET ± Palbociclib in HR-Positive, HER-Negative EBC

Immunotherapy in HR-Positive Breast Cancer

Conclusions

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.